Similar companies
| Company | Revenue | |
|---|---|---|
 |
Alzamend NeuroALZN |
0 N/A |
 |
enGenesENGN |
0 0% |
 |
Immunoprecise AntibodiesIPA |
5.3M 18.5% |
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Gross Profit | -15,000 | 0% |
| Cost of Revenue | 15,000 | 0% |
| Operating expense | 1.5M | 12.9% |
| Net Income | -2.1M | 130.6% |
| EBITDA | -810,000 | 52.1% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 8.2M | 7.6% |
| Total Liabilities | 4.7M | 11.9% |
| Total Equity | 3.5M | 25.2% |
| Shares Outstanding | 3.6M | 9.4% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | -1.1M | 5.5% |
| Cash from financing | 470,000 | 223.5% |
EPS
Financial Highlights for Clearmind Medicine Common Shares in Q3 '24
Gross Profit stood at -15,000, marking a 0% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 15,000, a 0% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 1.5M, showing a 12.9% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -2.1M, showing a -130.6% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -810,000, showing a 52.1% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Clearmind Medicine Common Shares faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. Higher operating expenses might indicate increased investments or potential inefficiencies.
